Management of basal cell carcinoma with pulmonary metastasis.

Fordham SA, Shao EX, Banney L, Azer M, Dettrick A. BMJ Case Rep. 2023 Jan 4;16(1):e251700. doi: 10.1136/bcr-2022-251700. PMID: 36599494; PMCID: PMC9815043.


A man in his 50s presented with an ulcerative lesion within the left axillary fold that had progressively worsened over 18 months. Biopsy revealed an ulcerative basal cell carcinoma (BCC), which was surgically managed. CT chest scans done 7 months later assessed post-treatment of radiotherapy. This revealed pulmonary lesions, which were biopsy-proven metastatic BCC. Sonidegib, a hedgehog signalling inhibitor, was used for first-line treatment. Due to progressive disease, sonidegib was ceased. Cemiplimab, a checkpoint inhibitor, was used as second-line treatment based on a phase II trial demonstrating efficacy in the setting of metastatic BCC. CT reports were initially consistent with response but after 6 months of cemiplimab treatment, repeat CT chest scans revealed a decrease in size of the previously cited pulmonary lesions.

This is a rare case of BCC metastases which has limited treatment options. This case provides insight of the patient experience on such treatment.